Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 325318, 15 pages
http://dx.doi.org/10.1155/2013/325318
Review Article

Chemokines in Chronic Liver Allograft Dysfunction Pathogenesis and Potential Therapeutic Targets

1Department of General Surgery, General Hospital of Tianjin Medical University, Tianjin 300052, China
2Department of Anesthesiology, General Hospital of Tianjin Medical University, Tianjin 300052, China
3Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

Received 4 August 2013; Accepted 3 October 2013

Academic Editor: Basak Kayhan

Copyright © 2013 Bin Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Despite advances in immunosuppressive drugs, long-term success of liver transplantation is still limited by the development of chronic liver allograft dysfunction. Although the exact pathogenesis of chronic liver allograft dysfunction remains to be established, there is strong evidence that chemokines are involved in organ damage induced by inflammatory and immune responses after liver surgery. Chemokines are a group of low-molecular-weight molecules whose function includes angiogenesis, haematopoiesis, mitogenesis, organ fibrogenesis, tumour growth and metastasis, and participating in the development of the immune system and in inflammatory and immune responses. The purpose of this review is to collect all the research that has been done so far concerning chemokines and the pathogenesis of chronic liver allograft dysfunction and helpfully, to pave the way for designing therapeutic strategies and pharmaceutical agents to ameliorate chronic allograft dysfunction after liver transplantation.